#### **GUIDED THERAPEUTICS INC**

```
Form SC 13G/A
October 07, 2015
```

```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Amendment No. 1)
Under the Securities Exchange Act of 1934
Guided Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $.0.001
(Title of Class of Securities)
40171F105
(CUSIP Number)
October 5, 2015
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule*
pursuant to which this Schedule is filed:
       Rule 13d-1(b)
Rule 13d-1(c)
     Rule 13d-1(d)
*The remainder of this cover page shall be filled \star
out for a reporting persons initial filing on this ^{\star}
form with respect to the subject class of securities, *
and for any subsequent amendment containing information *
which would alter the disclosures provided in a prior *
cover page.
The information required in the remainder of this cover*
page shall not be deemed to be filed for the purpose of *
Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise*
subject to the liabilities of that section of the Act but*
shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information*
contained in this form are not
required to respond unless the form displays a currently*
valid OMB control number.
13G/A
CUSIP No. 40171F105
                       Page 2 of 6
1. Names of Reporting Persons.
David B. Musket
2. Check the Appropriate Box if a Member of a Group
(a)
```

(b) 3. SEC Use Only 4. Citizenship or Place of Organization Massachusetts Number of Shares Beneficially Owned by Each Reporting Person With: 4,177,192 5. Sole Voting Power 6. Shared Voting Power 2,036,835 7. Sole Dispositive Power 4,177,192 8. Shared Dispositive Power 2,036,835 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,214,027 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9)\* 4.33% \* 12. Type of Reporting Person \* ΤN \* The percentage used above is calculated based on \* 143,629,234 shares outstanding on September30,2015 13G/A CUSIP No. 40171F105 Page 3 of 6 1. Names of Reporting Persons. ProMed Partners, LP 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 6. Shared Voting Power 2,036,835

7. Sole Dispositive Power

0

8. Shared Dispositive Power 2,036,835 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,036,835 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9)\* 1.42% \* 12. Type of Reporting Person \* ΡN \* The percentage used above is calculated based on \* 143,629,234 shares outstanding on September30,2015 13G/A CUSIP No. 40171F105\* Page 4 of 6 ITEM 1. (a) Name of Issuer: Guided Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices: 5835 Peachtree Corners, East, Suite D Norcross, GA 30092 ITEM 2. (a) Name of Person Filing: This statement is filed on behalf of the\* following entities (collectively, the Reporting Persons): (i) David B. Musket (ii) ProMed Partners, LP (b) Address of Principal Business Office, or if None, Residence: 180 Beacon Street, Suite 17A Boston, MA 02116 (c) Citizenship: (i) David B. Musket is an individual having citizenship in the United States (ii) ProMed Partners, LP is an investment partnership organized under the laws of the State of Delaware (d) Title of Class of Securities:

Common Stock, par value \$0.001 per share

```
(e) CUSIP Number: 40171F105
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO *
SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a)
[ ]
Broker or dealer registered under Section 15*
of the Act (15 U.S.C. 780).
(b)
[_]
Bank as defined in Section 3(a)(6) of the Act*
(15 U.S.C. 78c).
(C)
Insurance company as defined in Section 3*
(a) (19) of the Act (15 U.S.C. 78c).
(d)
[ ]
Investment company registered under Section *
8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)
[_]
An investment adviser in accordance with*
 ss.240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund*
in accordance with ss.240.13d-1(b)(1)(ii)(F);
(q)
A parent holding company or control person in*
accordance with ss.240.13d-1(b)(1)(ii)(G);
(h)
[_]
A savings associations as defined in Section*
3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
[_]
A church plan that is excluded from the *
definition of an investment company under section*
3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
[_]
Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
ITEM 4. OWNERSHIP.
Provide the following information regarding the*
 aggregate number and percentage of the class of*
 securities of the issuer identified in Item 1.
```

The information required by Items 4(a)-(c) is \* set forth in Rows 5-11 of the cover page for each Reporting Person hereto \* and is incorporated herein by 13G/A CUSIP No. 40171F105 Page 5 of 6 reference for each such Reporting Person. \* The percentage used above is calculated based on \* 143,629,234 shares outstanding on September30,2015 . . This filing relates to shares of the Issuer\* represented by common stock received from the \* conversion of Series C Convertible Preferred \* Stock and dividend shares earned from holdings \* of Series B and Series C Preferred stock in the \* quarter ended September, 30 2015 and not due to  $^{\star}$ the purchase or sale of shares in the open market. David B. Musket is the Managing Member of \* ProMed Asset Management. LLC which is the General Partner of ProMed Partners\* , LP. Mr. Musket disclaims beneficial ownership of the shares owned by \* ProMed Partners, LP except to the extent of his pecuniary interest therein. \* Mr. Musket is also the principal of Musket Research Associates, Inc. a registered broker-dealer.\* The shares owned by Mr. Musket were acquired in his individual capacity in \* the ordinary course of business and, at the time of such acquisition, did not have\* any agreements or understandings, directly or indirectly, with any person to \* distribute such securities. This amendment corrects the October 5, 2015  $^{\star}$ 13G filing by excluding ownership of all \* unconverted Series C Preferred shares, and \* unexercised Series B and Series C warrants. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON\* BEHALF OF ANOTHER PERSON. Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE\*

SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF \* MEMBERS OF THE GROUP. Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable ITEM 10. CERTIFICATIONS. By signing below I certify that, to the best of \* my knowledge and belief, the securities referred\* to above were acquired and are held in the ordinary course of business \* and were not acquired and not held for the purpose\* of or with the effect of changing or influencing the control of the \* issuer of the securities and were not acquired  $^{\star}$ and are not held in connection with or as a participant in any  $^{\star}$ transaction having such purpose or effect. 13G/A CUSIP No. 40171F105\* Page 6 of 6 SIGNATURE After reasonable inquiry and to the best of my\* knowledge and belief, I certify that the  $^{\star}$ information set forth in this statement is true, complete and correct. October 2, 2015 By: \_\_David B. Musket\_\_\_\_\* ProMed Partners, LP By:\_\_David B. Musket\_\_\_\_\_ Title: Managing Member